Overview
ImmuneOncia Therapeutics is a clinical-stage biopharmaceutical company specializing in immuno-oncology, developing novel antibodies and bispecific antibodies targeting PD-L1, CD47, and other pathways for cancers like refractory NK/T-cell lymphoma and hepatocellular carcinoma. Key pipeline candidates include Danburstotug (PD-L1 mAb) advancing to Phase III with Lonza manufacturing support, IMC-002 (anti-CD47), and IOH-001 (CD47/PD-L1 bispecific). The company leverages expertise in drug development and antibody engineering from its headquarters in Yongin-si, South Korea.
Frequently asked questions
- What are ImmuneOncia's key pipeline products?
- Key candidates include Danburstotug (PD-L1 targeting mAb for refractory NK/T-cell lymphoma entering Phase III), IMC-002 (anti-CD47 for HCC with 50% disease control rate in trials), IOH-001 (CD47/PD-L1 bispecific showing superior tumor suppression), and IMC-201 (selective cancer cell binder).
- What manufacturing capabilities does ImmuneOncia use?
- ImmuneOncia partners with Lonza for end-to-end cGMP manufacturing of Danburstotug at sites in Slough (UK), Basel, and Stein (Switzerland), supporting clinical supply.
- Where is ImmuneOncia located and what is their therapeutic focus?
- Headquartered in Yongin-si, South Korea, ImmuneOncia focuses on immuno-oncology therapies using antibody engineering for solid and hematological cancers.